Behe M - Search Results

1

Cholecystokinin 2 Receptor Agonist ¹⁷⁷Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study.

Rottenburger C, Nicolas GP, McDougall L, Kaul F, Cachovan M, Vija AH, Schibli R, Geistlich S, Schumann A, Rau T, Glatz K, Behe M, Christ ER, Wild D. Rottenburger C, et al. Among authors: behe m. J Nucl Med. 2020 Apr;61(4):520-526. doi: 10.2967/jnumed.119.233031. Epub 2019 Sep 13. J Nucl Med. 2020. PMID: 31519804 Free PMC article. Clinical Trial.

2

DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy.

Otte A, Jermann E, Behe M, Goetze M, Bucher HC, Roser HW, Heppeler A, Mueller-Brand J, Maecke HR. Otte A, et al. Among authors: behe m. Eur J Nucl Med. 1997 Jul;24(7):792-5. doi: 10.1007/BF00879669. Eur J Nucl Med. 1997. PMID: 9211767

3

Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.

Behr TM, Jenner N, Radetzky S, Béhe M, Gratz S, Yücekent S, Raue F, Becker W. Behr TM, et al. Among authors: behe m. Eur J Nucl Med. 1998 Apr;25(4):424-30. doi: 10.1007/s002590050241. Eur J Nucl Med. 1998. PMID: 9553173

4

Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.

Behr TM, Jenner N, Béhé M, Angerstein C, Gratz S, Raue F, Becker W. Behr TM, et al. Among authors: behe m. J Nucl Med. 1999 Jun;40(6):1029-44. J Nucl Med. 1999. PMID: 10452322 Free article.

5

Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.

Behr TM, Béhé MP. Behr TM, et al. Among authors: behe mp. Semin Nucl Med. 2002 Apr;32(2):97-109. doi: 10.1053/snuc.2002.31028. Semin Nucl Med. 2002. PMID: 11965605 Review.

6

Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.

Béhé M, Kluge G, Becker W, Gotthardt M, Behr TM. Béhé M, et al. J Nucl Med. 2005 Jun;46(6):1012-5. J Nucl Med. 2005. PMID: 15937313 Free article.

7

Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?

Storch D, Béhé M, Walter MA, Chen J, Powell P, Mikolajczak R, Mäcke HR. Storch D, et al. Among authors: behe m. J Nucl Med. 2005 Sep;46(9):1561-9. J Nucl Med. 2005. PMID: 16157541 Free article.

8

[Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.

Wild D, Béhé M, Wicki A, Storch D, Waser B, Gotthardt M, Keil B, Christofori G, Reubi JC, Mäcke HR. Wild D, et al. Among authors: behe m. J Nucl Med. 2006 Dec;47(12):2025-33. J Nucl Med. 2006. PMID: 17138746 Free article.

9

[Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.

Wicki A, Wild D, Storch D, Seemayer C, Gotthardt M, Behe M, Kneifel S, Mihatsch MJ, Reubi JC, Mäcke HR, Christofori G. Wicki A, et al. Among authors: behe m. Clin Cancer Res. 2007 Jun 15;13(12):3696-705. doi: 10.1158/1078-0432.CCR-06-2965. Clin Cancer Res. 2007. PMID: 17575235

10

Exendin-4-based radiopharmaceuticals for glucagonlike peptide-1 receptor PET/CT and SPECT/CT.

Wild D, Wicki A, Mansi R, Béhé M, Keil B, Bernhardt P, Christofori G, Ell PJ, Mäcke HR. Wild D, et al. Among authors: behe m. J Nucl Med. 2010 Jul;51(7):1059-67. doi: 10.2967/jnumed.110.074914. J Nucl Med. 2010. PMID: 20595511 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters